The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Annie Samuel - JPMorgan - Analyst
: Perfect. Thanks so much, Matt. That was an incredibly informative presentation. I feel like I have so many questions to ask. But the first one I want
to start with is it's been a little bit under a year since you've been a public company.
And I was just wondering maybe what some of your big takeaways over this time period have been both from the marketplace and just kind of
the overall reception across your stakeholders. Sometimes what we hear from newly public companies is that it kind of helps our brand recognition.
It kind of like helps the pipeline a little bit because people know you, they understand you a little bit more. Your financials are public and they know
that they can trust you. As you talked about, you have really great trust.
So just curious, how has being a public company impacted you over that time?
Question: Annie Samuel - JPMorgan - Analyst
: That's great to hear. You sit in a unique area of the provider market in that you're really a mission-critical solution. And all of these providers have
just been facing issues with labor shortages and trying to get paid because they've had such low margins. So can you speak to maybe the resiliency
of demand for the revenue cycle solutions space, the needs that you're addressing? And what's the status quo?
What are you replacing?
Question: Annie Samuel - JPMorgan - Analyst
: That was going to be one of my other questions is just around this kind of Altitude product. How receptive are your customers today to kind of
leveraging AI? Because health care is always so slow, right, but everyone is very interested in AI, and it seems like it's really kind of a real problem
solver. Administrative burden seems like such a natural place for AI to kind of help. NVIDIA spoke today about like really splashy stuff like robots
and all that kind of stuff, but it feels like this is really the nuts and bolts of where AI is going to be helpful for the health care system and they might
be willing to adopt it.
So can you just maybe talk about that? Where is the next step or what's the low-hanging fruit for you around AI?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JANUARY 13, 2025 / 7:15PM, WAY.OQ - Waystar Holding Corp at JPMorgan Healthcare Conference
Question: Annie Samuel - JPMorgan - Analyst
: That's great. I feel like we only have a little bit of time, but I feel like I would be remiss if I didn't ask you about. You said something really interesting,
I thought, in that in order to kind of hit your 10% growth algorithm, you don't need any incremental solutions. You can do it with what you have
today. And I'm curious, you had this bolus of new customers that came on from the Change cyberattack.
So how should we be thinking about the contributions from new client growth, cross-sell, upsell within that kind of long-term growth algorithm?
And has that changed at all coming out of the Change cyberattack?
Question: Annie Samuel - JPMorgan - Analyst
: Terrific. Well, we have 40 seconds left. What are you most excited for in 2025?
Question: Annie Samuel - JPMorgan - Analyst
: That's great. So much opportunity for improvement in the health care system.
Question: Annie Samuel - JPMorgan - Analyst
: Thank you so much for joining us today.
| 
